Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II capivasertib monotherapy in PI3K pathway–activated biliary tract cancer
jRCTs031250049Phase 2Suspended
- Sponsor
- Yokohama City University
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capivasertib in biliary cancer, sponsored by Yokohama City University. Primary endpoint: Objective response rate. Started Jun 2025; status: suspended.
02
Drugs
capivasertib
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCTs031250049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250049.